Back to search results

Study of ONC206 for Advanced Pheochromocytoma and Paraganglioma

This study is testing a drug called ONC206 (also known as JZP3507) in people with advanced pheochromocytoma and paraganglioma (PCPG), which are rare types of tumors. The main goal is to see how many participants respond to the treatment. You might be able to join if you are 18 or older, have PCPG that can't be removed by surgery, and have already tried or can't receive standard treatments. This study is currently enrolling participants and plans to include 90 people.

Study design
This is a two-stage Phase 2 study. In Stage 1, all participants will receive ONC206. If enough participants respond, the study will move to Stage 2 where participants will be randomly assigned to one of two ONC206 dose levels.
What's involved
Participants will receive ONC206 twice daily, three days a week, in 28-day cycles. The study will monitor your response for up to 36 months.
Compensation
Not stated in the trial record.
Follow-up
Your response to treatment will be measured for up to 36 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07282587

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Jazz Pharmaceuticals
~90 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:ONC206ONC206: Dose 1ONC206: Dose 2

At a glance

Recruiting sites
7 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured over Up to 36 months.

Conditions

Advanced Pheochromocytoma and Paraganglioma
PCPG

Explore related trials

Adrenal Gland PheochromocytomaParaganglioma

NCT07282587

Where you'd take part

This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Columbia University Medical Center

    New York, New Yorkno site contact published

    Not yet recruiting

  • Mayo-Rochester

    Rochester, Minnesotano site contact published

    Recruiting

  • PENN

    Philadelphia, Pennsylvaniano site contact published

    Recruiting

  • Stanford

    Palo Alto, Californiano site contact published

    Recruiting

  • U of Colorado

    Aurora, Coloradono site contact published

    Recruiting

  • U of Michigan

    Ann Arbor, Michiganno site contact published

    Not yet recruiting

  • UCLA

    Los Angeles, Californiano site contact published

    Recruiting

  • UTAH

    Salt Lake City, Utahno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Clinical Trial Disclosure & Transparency
[email protected]
215-832-3750
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

a. Any prior anticancer therapy or investigational agents within 4 weeks or 5 half-lives, whichever is shorter. Note: Denosumab and zoledronic acid are permissible.
b. Strong cytochrome P450 (CYP) inhibitors within 14 days. c. Strong CYP inducers within 14 days. d. Any radiotherapy within 14 days. e. Any major surgery, open biopsy or significant traumatic injury within 1 month (30 days). 6. Is pregnant, breastfeeding, or planning to become pregnant while receiving study treatment or within 3 months after the last dose. 7. Has uncontrolled intercurrent illness or any other medical, psychiatric, or social condition that, in the opinion of the Investigator, may interfere with participant safety or the ability to comply with study requirements. 8. Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) not yet resolved to the National Cancer Institute Common Terminology Criteria for Adverse Events Grade ≤1, or baseline and considered clinically significant; consult with Medical Monitor. 9. Has an active infection that requires systemic therapy.

What this trial measures

  • Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Up to 36 months.

    ORR defined as the number of participants with a confirmed complete response (CR) or partial response during the study, as per RECIST v1.1.